Lyso-Globotriaosylceramide (d18:1) T37291
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mg | 126550-86-5 | ¥11,700.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Lyso-Globotriaosylceramide (d18:1)
描述: Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Chloroform:Methanol:H2O (4:3:1) : Soluble
关键字: LysoGlobotriaosylceramide (d18:1) | Lyso Globotriaosylceramide (d18:1) | Lyso-Globotriaosylceramide | Lyso-Globotriaosylceramide (d-18:1) | d18:1
Lyso-Globotriaosylceramide (d18:1) T37291信息由TargetMol中国为您提供,如您想了解更多关于Lyso-Globotriaosylceramide (d18:1) T37291报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途